Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Recipharm in New German Market Collaboration with FHS Unternehmensberatung

Published: Wednesday, October 16, 2013
Last Updated: Wednesday, October 16, 2013
Bookmark and Share
FHS Unternehmensberatung to sell and market Recipharm’s development services to customers.

FHS Unternehmensberatung and Recipharm Pharmaceutical Development AB based in Stockholm have announced that they have entered into a collaboration.

FHS Unternehmensberatung will sell and market Recipharm’s development services, including formulation development, analytical development, manufacture of clinical trial material and stability studies, to customers in Austria, Germany and Switzerland.

“I am very excited about this collaboration”, says Torkel Gren, Sales Director, Recipharm Pharmaceutical Development AB. “FHS Unternehmensberatung has through its owner Fritz H. Speck an excellent knowledge of the contract development business and a very valuable network in German speaking countries. I am convinced that this will help us to reach out to new customers”.

“I am deeply impressed by the capabilities, the excellent experience and the staff's extraordinary team spirit at Recipharm PD” says Fritz Speck, owner of FHS Unternehmensberatung.

Speck continued, “To me it seems quite clear, that especially clients in the German-speaking market could benefit a lot from the attractive opportunities and multilingual experience at Recipharm PD. I look forward to a successful and pleasant cooperation with the team.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Recipharm Reaches Agreement with LobSor Pharmaceuticals
Agreement to manufacture LECIGON™, a proprietary treatment for advanced Parkinson’s disease.
Thursday, September 10, 2015
Recipharm Signs Agreement with RedHill Biopharma
Agreement for manufacturing of RHB-105 for treatment of H. pylori infection.
Thursday, August 27, 2015
Recipharm Secures Additional Bank Financing for Continued Growth
Company has entered a new five-year SEK 1 500 million term loan facility with three of the largest banks.
Tuesday, July 14, 2015
Recipharm Invests SEK 8 Million in Pharmanest
Investment to support the development of Pharmanest’s lead drug candidate SHACT.
Friday, July 10, 2015
Recipharm Reduces Risk and Improves Compliance with Infor
Company will also help Recipharm continue to improve compliance with the EU-GMP code of practice.
Thursday, July 09, 2015
Recipharm Appoints New Sales Director, Development Services
Amine Tahiri has joined the Development Services Sales team with effect from 1 July 2015.
Tuesday, June 30, 2015
Recipharm Acquires OnTarget Chemistry
Company extends its offering into preclinical development services.
Tuesday, June 16, 2015
Recipharm Appoints Chief Strategy Officer
Company has appointed Jean-François Hilaire to the new position of CSO.
Thursday, June 04, 2015
Recipharm Signs Partnership Agreement with Follicum
Agreement in preparation for a clinical trial of the drug candidate FOL-005.
Thursday, June 04, 2015
Recipharm Appoints New General Manager
Appointment of Giorgio Bruno as General Manager of Recipharm Italia S.p.A.
Thursday, April 30, 2015
Recipharm is Commencing Negotiations with LIDDS
Collaboration on large-scale manufacture of Liproca® Depot.
Friday, April 24, 2015
Recipharm Makes Strategic Investment in Synthonics
Recipharm has purchased $2.0 million of preferred stock in the company.
Wednesday, April 15, 2015
Recipharm and Adroit Science Form Collaboration
Company will support Recipharm’s pharmaceutical development with high quality solid state characterization services.
Thursday, March 26, 2015
Recipharm Completes Korean Serialization Project for Abbott
Validation batches planned to be shipped to Korea mid-March 2015.
Thursday, March 19, 2015
Recipharm Appoints New Position of Vice President Quality Management
Appointment of Thomas Beck with effect from 1st April 2015.
Wednesday, March 11, 2015
Scientific News
Researchers Develop Classification Model for Cancers Caused by KRAS
Most frequently mutated cancer gene help oncologists choose more effective cancer therapies.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Chromosomal Chaos
Penn study forms basis for future precision medicine approaches for Sezary syndrome
Enzyme Malfunction May be Why Binge Drinking Can Lead to Alcoholism
A new study in mice shows that restoring the synthesis of a key brain chemical tied to inhibiting addictive behavior may help prevent alcohol cravings following binge drinking.
Key to Natural Detoxifier’s Reactivity Discovered
Results have implications for health, drug design and chemical synthesis.
New Treatment for Obesity Developed
Researchers at the University of Liverpool, working with a global healthcare company, have helped develop a new treatment for obesity.
New Protein Found in Immune Cells
Immunobiologists from the University of Freiburg discover Kidins220/ARMS in B cells and demonstrate its functions.
Will Brain Palpation Soon Be Possible?
Researchers have developed non-invasive brain imaging technique which provides the same information as physical palpation.
Shaking Up the Foundations of Epigenetics
Researchers at the Centre for Genomic Regulation (CRG) and the University of Barcelona (UB) published a study that challenges some of the current beliefs about epigenetics.
Groundbreaking Computer Program Diagnoses Cancer in Two Days
Researchers have combined genetics with computer science and created a new diagnostic technology can with 85 per cent certainty identify the source of the disease and thus target treatment and, ultimately, improve the prognosis for the patient.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos